| scholarly article | Q13442814 |
| P2093 | author name string | Yu Peng | |
| Andrew D Napper | |||
| Katherine M Drake | |||
| Venita Gresham Watson | |||
| P2860 | cites work | The mixed-lineage leukemia fusion partner AF4 stimulates RNA polymerase II transcriptional elongation and mediates coordinated chromatin remodeling | Q40202913 |
| The synthetic peptide PFWT disrupts AF4-AF9 protein complexes and induces apoptosis in t(4;11) leukemia cells | Q40532537 | ||
| New insights to the MLL recombinome of acute leukemias | Q44945193 | ||
| The MLL recombinome of acute leukemias | Q56965972 | ||
| An atlas of chromosomes in hematological malignancies. Example: 11q23 and MLL partners | Q74060943 | ||
| Rational design of the first small-molecule antagonists of NHERF1/EBP50 PDZ domains | Q80459449 | ||
| The minimum significant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies | Q82615309 | ||
| Leukemia fusion target AF9 is an intrinsically disordered transcriptional regulator that recruits multiple partners via coupled folding and binding. | Q27675570 | ||
| A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays | Q28145712 | ||
| The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability | Q29547634 | ||
| New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays | Q29615588 | ||
| BioAssay ontology annotations facilitate cross-analysis of diverse high-throughput screening data sets | Q33864494 | ||
| MLL fusion partners AF4 and AF9 interact at subnuclear foci | Q34275143 | ||
| MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia | Q34571591 | ||
| MLL-rearranged leukemias: insights from gene expression profiling | Q35569555 | ||
| In search of targeted therapies for childhood cancer | Q35971733 | ||
| Peptide, peptidomimetic and small-molecule drug discovery targeting HIV-1 host-cell attachment and entry through gp120, gp41, CCR5 and CXCR4. | Q36402572 | ||
| The AF4-mimetic peptide, PFWT, induces necrotic cell death in MV4-11 leukemia cells | Q36502377 | ||
| Xenograft models for the preclinical evaluation of new therapies in acute leukemia | Q36799846 | ||
| HOXA9 is required for survival in human MLL-rearranged acute leukemias | Q37129652 | ||
| Molecular targeting of MLL-rearranged leukemia cell lines with the synthetic peptide PFWT synergistically enhances the cytotoxic effect of established chemotherapeutic agents | Q37260555 | ||
| The molecular biology of mixed lineage leukemia | Q37522825 | ||
| MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia | Q38294261 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 253-268 | |
| P577 | publication date | 2013-05-01 | |
| P1433 | published in | Assay and Drug Development Technologies | Q15767279 |
| P1476 | title | Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology | |
| P478 | volume | 11 |
| Q35571730 | Binding cavities and druggability of intrinsically disordered proteins |
| Q38728681 | Current Experimental Methods for Characterizing Protein-Protein Interactions |
| Q64087496 | Modulation of Disordered Proteins with a Focus on Neurodegenerative Diseases and Other Pathologies |
| Q91789005 | Peptidomimetics for Targeting Protein-Protein Interactions between DOT1L and MLL Oncofusion Proteins AF9 and ENL |
| Q35824701 | Protein-protein interactions as drug targets |
| Q36989223 | Targeted drug discovery for pediatric leukemia |
Search more.